Sandostatin and the Belfast experience

Digestion. 1990;45 Suppl 1:11-4; discussion 15-6. doi: 10.1159/000200255.

Abstract

Twenty-four patients with 26 apudomas have been treated with Sandostatin (octreotide) in Belfast. The 2 patients with vipoma showed an excellent response clinically and biochemically. Of 15 patients with carcinoids, Sandostatin improved the diarrhoea in 70%, flush in 58%, and wheeze in 100% of patients. Patients with insulinoma and the Zollinger-Ellison syndrome were unresponsive to Sandostatin. In general, the response to Sandostatin appeared to decline as the tumour size increased and tumour markers rose. Side effects have not been a problem.

MeSH terms

  • Apudoma / drug therapy*
  • Carcinoid Tumor / drug therapy
  • Diarrhea / drug therapy
  • Female
  • Flushing / drug therapy
  • Gastrinoma / drug therapy
  • Humans
  • Insulinoma / drug therapy
  • Northern Ireland
  • Octreotide / therapeutic use*
  • Respiratory Sounds
  • Vipoma / drug therapy
  • Zollinger-Ellison Syndrome / drug therapy

Substances

  • Octreotide